NCT07697833Not yet recruitingPhase 4
Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients
Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Patients With Heart Failure and Reduced Ejection Fraction: Randomized, Placebo-controlled, Parallel-group, Double-blind Trial
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
To compare the effectiveness and safety of Vericiguat with Standard Medical Treatment in Patients with Heart Failure and Reduced Ejection Fraction
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 30 Jun 2026
- Start date
- 15 Jul 2026
- Primary completion date
- 15 May 2027
- Lead sponsor
- National Institute of Cardiovascular Diseases, Pakistan
- Diseases
- Heart failure
- NCT number
- NCT07697833
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 500
- From 15 Jul 2026 to the primary completion date, 15 May 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent or anticipated use of long-acting nitrates.
Other illness
- Not on standard of care medical treatment for heart failure.
Other
- Systolic blood pressure of less than 100 mm Hg.
- Use of intravenous inotropes or implantable left ventricular assist devices.
- Unwillingness to give consent
Who the study is looking for
- Age \>18 years of any gender
- Chronic heart failure (New York Heart Association \[NYHA\] functional class II, III, or IV), a reduced left ventricular ejection fraction of less than 45% within 12 months before randomization
- Elevated natriuretic peptide level: (For patients in sinus rhythm, the criteria include a plasma B-type natriuretic peptide (BNP) level of at least 300 pg per milliliter or an NT-proBNP level of at least 1000 pg per milliliter. For patients in atrial fibrillation, the criteria included a BNP level of at least 500 pg per milliliter or an NT-proBNP level of at least 1600 pg per milliliter).
- Evidence of worsening heart failure.
- The percentage of enrolled patients with an estimated glomerular filtration rate of 15 to 30 ml per minute per 1.73 m2 of body-surface area was capped at 15%.
- Patients on guideline-based medical therapy 3 months
- Written and informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.